At its meeting of 8 May 2023, the Transparency Council adopted Opinion No. 92/2023 on the inclusion in the reimbursement procedure of medicines containing the active substances telmisartan + indapamide for selected off-label indications.
Publication on the list of opinions on active substances for off-label indications